Gsα, Pseudohypoparathyroidism, Fibrous Dysplasia, and McCune-Albright Syndrome

Genetics of Bone Biology and Skeletal Disease

Volumn , Issue , 2013, Pages 425-440

  Weinstein, Lee S ^a   Collins, Michael T ^b   Spiegel, Allen M ^c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883918977     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387829-8.00027-5     Document Type: Chapter

References (99)

1. sα (GNAS1): fibrous dysplasia, McCune-Albright syndrome, Albright hereditary osteodystrophy, and pseudohypoparathyroidism. Inborn errors of development: the molecular basis of clinical disorders of morphogenesis 2008, 1277-1288. Oxford University Press, New York. 2nd ed. C.J. Epstein, R.P. Erickson, A. Wynshaw-Boris (Eds.).
2. Long DN, Levine MA, Germain-Lee EL Bone mineral density in pseudohypoparathyroidism type 1a. J Clin Endocrinol Metab 2010, 95:4465-4475.
3. Costello JM, Dent CE Hypo-hyperparathyroidism. Arch Dis Child 1963, 38:397-407.
4. Namnoum AB, Merriam GR, Moses AM, Levine MA Reproductive dysfunction in women with Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 1998, 83:824-829.
5. Germain-Lee EL, Groman J, Crane JL, Jan de Beur SM, Levine MA Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab 2003, 88:4059-4069.
6. s in the development of human obesity. J Clin Endocrinol Metab 2007, 92:1073-1079.
7. sα is imprinted in human thyroid glands: implications for thyroid function in pseudohypoparathyroidism types 1A and 1B. J Clin Endocrinol Metab 2003, 88:4336-4341.
8. Mantovani G, Bondioni S, Linglart A, et al. Genetic analysis and evaluation of resistance to thyrotropin and growth hormone-releasing hormone in pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 2007, 92:3738-3742.
9. Kaplan FS, Shore EI Progressive osseous heteroplasia. J Bone Miner Res 2000, 15:2084-2094.
10. de Sanctis L, Vai S, Andreo MR, Romagnolo D, Silvestro L, de Sanctis C Brachydactyly in 14 genetically characterized pseudohypoparathyroidism type Ia patients. J Clin Endocrinol Metab 2004, 89:1650-1655.
11. Joseph AW, Shoemaker AH, Germain-Lee EL Increased prevalence of carpal tunnel syndrome in albright hereditary osteodystrophy. J Clin Endocrinol Metab 2011, 96:2065-2073.
12. sα. Clin Endocrinol (Oxf) 2008, 68:233-239.
13. Shore EM, Ahn J, Jan de Beur S, et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002, 346:99-106.
14. Juppner H, Schipani E, Bastepe M, et al. The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3. Proc Natl Acad Sci USA 1998, 95:11798-11803.
15. sα and its role in metabolic regulation. Cell Metab 2009, 9:548-555.
16. sα and the possible role of alternative gene products of GNAS in Albright hereditary osteodystrophy and pseudohypoparathyroidism type Ia. Exp Clin Endocrinol Diabetes 2010, 118:127-132.
17. sα -L deficiency. J Clin Endocrinol Metab 2007, 92:1764-1768.
18. sα gene (GNAS1) in patients with Albright hereditary osteodystrophy. Hum Mol Genet 1995, 4:2001-2002.
19. Liu J, Nealon JG, Weinstein LS Distinct patterns of abnormal GNAS imprinting in familial and sporadic pseudohypoparathyroidism type IB. Hum Mol Genet 2005, 14:95-102.
20. Bastepe M, Frohlich LF, Hendy GN, et al. Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest 2003, 112:1255-1263.
21. Bastepe M, Frohlich LF, Linglart A, et al. Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat Genet 2005, 37:25-27.
22. Chillambhi S, Turan S, Hwang DY, Chen HC, Juppner H, Bastepe M Deletion of the noncoding GNAS antisense transcript causes pseudohypoparathyroidism type Ib and biparental defects of GNAS methylation in cis. J Clin Endocrinol Metab 2010, 95:3993-4002.
23. Fernandez-Rebollo E, Perez de Nanclares G, Lecumberri B, et al. Exclusion of the GNAS locus in PHP-Ib patients with broad GNAS methylation changes: evidence for an autosomal recessive form of PHP-Ib?. J Bone Miner Res 2011, 26:1854-1863.
24. Bastepe M, Altug-Teber O, Agarwal C, Oberfield SE, Bonin M, Juppner H Paternal uniparental isodisomy of the entire chromosome 20 as a molecular cause of pseudohypoparathyroidism type Ib (PHP-Ib). Bone 2011, 48:659-662.
25. Linglart A, Bastepe M, Juppner H Similar clinical and laboratory findings in patients with symptomatic autosomal dominant and sporadic pseudohypoparathyroidism type Ib despite different epigenetic changes at the GNAS locus. Clin Endocrinol (Oxf) 2007, 67:822-831.
26. αs. A cause of pseudohypoparathyroidism type Ib. J Biol Chem 2001, 276:165-171.
27. sα gene Gnas using gene targeting technology. Pharmacol Ther 2007, 115:271-291.
28. Huso DL, Edie S, Levine MA, et al. Heterotopic ossifications in a mouse model of albright hereditary osteodystrophy. PLoS One 2011, 6:e21755.
29. Plagge A, Gordon E, Dean W, et al. The imprinted signaling protein XLαs is required for postnatal adaptation to feeding. Nat Genet 2004, 36:818-826.
30. Xie T, Plagge A, Gavrilova O, et al. The alternative stimulatory G protein α-subunit XLαs is a critical regulator of energy and glucose metabolism and sympathetic nerve activity in adult mice. J Biol Chem 2006, 281:18989-18999.
31. sα imprint control region. Endocrinology 2008, 149:2443-2450.
32. Frohlich LF, Bastepe M, Ozturk D, Abu-Zahra H, Juppner H Lack of Gnas epigenetic changes and pseudohypoparathyroidism type Ib in mice with targeted disruption of syntaxin-16. Endocrinology 2007, 148:2925-2935.
33. Frohlich LF, Mrakovcic M, Steinborn R, Chung UI, Bastepe M, Juppner H Targeted deletion of the Nesp55 DMR defines another Gnas imprinting control region and provides a mouse model of autosomal dominant PHP-Ib. Proc Natl Acad Sci USA 2010, 107:9275-9280.
34. Stone MD, Hosking DJ, Garcia-Himmelstine C, White DA, Rosenblum D, Worth HG The renal response to exogenous parathyroid hormone in treated pseudohypoparathyroidism. Bone 1993, 14:727-735.
35. s deficiency. J Clin Endocrinol Metab 1999, 84:4127-4131.
36. Dekelbab BH, Aughton DJ, Levine MA Pseudohypoparathyroidism type 1A and morbid obesity in infancy. Endocr Pract 2009, 15:249-253.
37. sα leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation. J Bone Miner Res 2005, 20:663-671.
38. Bastepe M, Weinstein LS, Ogata N, et al. Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo. Proc Natl Acad Sci USA 2004, 101:14794-14799.
39. Mariot V, Maupetit-Mehouas S, Sinding C, Kottler ML, Linglart A A maternal epimutation of GNAS leads to Albright osteodystrophy and parathyroid hormone resistance. J Clin Endocrinol Metab 2008, 93:661-665.
40. Mantovani G, de Sanctis L, Barbieri AM, et al. Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of Albright hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab 2010, 95:651-658.
41. sα activity is reduced in erythrocyte membranes of patients with psedohypoparathyroidism due to epigenetic alterations at the GNAS locus. J Bone Miner Res 2011, 26:1864-1870.
42. sα-receptor interaction. Hum Mutat 2011, 32:653-660.
43. Linglart A, Menguy C, Couvineau A, et al. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N Engl J Med 2011, 364:2218-2226.
44. Lietman SA, Goldfarb J, Desai N, Levine MA Preimplantation genetic diagnosis for severe Albright hereditary osteodystrophy. J Clin Endocrinol Metab 2008, 93:901-904.
45. Mantovani G, Ferrante E, Giavoli C, et al. Recombinant human GH replacement therapy in children with pseudohypoparathyroidism type Ia: first study on the effect on growth. J Clin Endocrinol Metab 2010, 95:5011-5017.
46. McCune DJ, Bruch H Osteodystrophia fibrosa: report of a case in which the condition was combined with precocious puberty, pathologic pigmentation of the skin and hyperthyroidism, with a review of the literature. Am J Dis Child 1937, 54:806-848.
47. Albright F, Butler AM, Hampton AO, Smith PH Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females, report of five cases. N Engl J Med 1937, 216:727-746.
48. Cremonini N, Graziano E, Chiarini V, Sforza A, Zampa GA Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995-Bromocriptine combined treatment results. J Clin Endocrinol Metab 1992, 75:1166-1169.
49. Benjamin DR, McRoberts JW Polyostotic fibrous dysplasia associated with Cushing syndrome. Arch Pathol 1973, 96:175-178.
50. Ryan WG, Nibbe AF, Schwartz TB, Ray RD Fibrous dysplasia of bone with vitamin D resistant rickets: a case study. Metabolism 1968, 17:988-998.
51. Mazabraud A, Girard J Un cas particulier de dysplasia localisations osseus et tendineuses. Rev Rhum Mal Osteartic 1957, 34:652-659.
52. Silva ES, Lumbroso S, Medina M, Gillerot Y, Sultan C, Sokal EM Demonstration of McCune-Albright mutations in the liver of children with high γGT progressive cholestasis. J Hepatol 2000, 32:154-158.
53. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991, 325:1688-1695.
54. Zacharin M, Bajpai A, Chow CW, et al. Gastrointestinal polyps in McCune Albright syndrome. J Med Genet 48: 458-61.
55. Bajpai A, Greenway A, Zacharin M Platelet dysfunction and increased bleeding tendency in McCune-Albright syndrome. J Pediatr 2008, 153:287-289.
56. Collins MT, Singer FR, Eugster E McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis 2012, 7(Supp1):S4.
57. sα mutations. J Clin Endocrinol Metab 2003, 88:4413-4417.
58. Huston TL, Simmons RM Ductal carcinoma in situ in a 27-year-old woman with McCune-Albright syndrome. Breast J 2004, 10:440-442.
59. Jenkins PJ Cancers associated with acromegaly. Neuroendocrinology 2006, 83:218-223.
60. Ruggieri P, Sim FH, Bond JR, Unni KK Malignancies in fibrous dysplasia. Cancer 1994, 73:1411-1424.
61. s protein in monostotic fibrous lesions of bone. J Orthop Res 1996, 14:311-315.
62. Collins MT, Chebli C, Jones J, et al. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 2001, 16:806-813.
63. Leet AI, Chebli C, Kushner H, et al. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res 2004, 19:571-577.
64. Cutler CM, Lee JS, Butman JA, et al. Long-term outcome of optic nerve encasement and optic nerve decompression in patients with fibrous dysplasia: risk factors for blindness and safety of observation. Neurosurgery 2006, 59:1011-1017.
65. Akintoye SO, Lee JS, Feimster T, et al. Dental characteristics of fibrous dysplasia and McCune-Albright syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontics 2003, 96:275-282.
66. Leet AI, Magur E, Lee JS, Wientroub S, Robey PG, Collins MT Fibrous dysplasia in the spine: prevalence of lesions and association with scoliosis. J Bone Joint Surg Am 2004, 86-A:531-537.
67. Diaz A, Danon M, Crawford J McCune-Albright syndrome and disorders due to activating mutations of GNAS1. J Pediatr Endocrinol Metab 2007, 20:853-880.
68. Delaney D, Diss TC, Presneau N, et al. GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod Pathol 2009, 22:718-724.
69. Idowu BD, Al-Adnani M, O'Donnell P, et al. A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. Histopathology 2007, 50:691-704.
70. Rey RA, Venara M, Coutant R, et al. Unexpected mosaicism of R201H-GNAS1 mutant-bearing cells in the testes underlie macro-orchidism without sexual precocity in McCune-Albright syndrome. Hum Mol Genet 2006, 15:3538-3543.
71. Mantovani G, Lania AG, Spada A GNAS imprinting and pituitary tumors. Mol Cell Endocrinol 2010, 326:15-18.
72. Mariot V, Wu JY, Aydin C, et al. Potent constitutive cyclic AMP-generating activity of XLαs implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone. Bone 2011, 48:312-320.
73. Zeiger MA, Saji M, Gusev Y, et al. Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. Endocrinology 1997, 138:3133-3140.
74. sα. J Mol Cell Cardiol 2010, 48:591-599.
75. sα signaling disrupts associative and spatial learning. Learn Mem 2006, 13:745-752.
76. sα-mutated skeletal progenitor cells. J Clin Invest 1998, 101:1737-1744.
77. Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. Am J Pathol 1997, 151:1587-1600.
78. Piersanti S, Remoli C, Saggio I, et al. Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors. J Bone Miner Res 2010, 25:1103-1116.
79. Riminucci M, Gehron Robey P, Saggio I, Bianco P Skeletal progenitors and the GNAS gene: fibrous dysplasia of bone read through stem cells. J Mol Endocrinol 2010, 45:355-364.
80. Kuznetsov SA, Cherman N, Riminucci M, Collins MT, Robey PG, Bianco P Age-dependent demise of GNAS-mutated skeletal stem cells and "normalization" of fibrous dysplasia of bone. J Bone Miner Res 2008, 23:1731-1740.
81. Karadag A, Riminucci M, Bianco P, et al. A novel technique based on a PNA hybridization probe and FRET principle for quantification of mutant genotype in fibrous dysplasia/McCune-Albright syndrome. Nucleic Acids Res 2004, 32:e63.
82. Wagoner HA, Steinmetz R, Bethin KE, Eugster EA, Pescovitz OH, Hannon TS GNAS mutation detection is related to disease severity in girls with McCune-Albright syndrome and precocious puberty. Pediatr Endocrinol Rev 2007, 4(Suppl. 4):395-400.
83. sα gene: site-specific patterns and recurrent histological hallmarks. J Pathol 1999, 187:249-258.
84. Hart ES, Kelly MH, Brillante B, et al. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia, and the relationship to functional outcome. J Bone Miner Res 2007, 22:1468-1474.
85. Feuillan PP, Foster CM, Pescovitz OH, et al. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986, 315:1115-1119.
86. Celi FS, Coppotelli G, Chidakel A, et al. The role of type-1 and type-2 5′ deiodinase in the pathophysiology of the T3 toxicosis of McCune-Albright syndrome. J Clin Endocrinol Metab 2008, 93:2383-2389.
87. Brown RJ, Kelly MH, Collins MT Cushing syndrome in the McCune-Albright syndrome. J Clin Endocrinol Metab 2010, 95:1508-1515.
88. Corsi A, Collins MT, Riminucci M, et al. Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. J Bone Miner Res 2003, 18:1235-1246.
89. Akintoye SO, Chebli C, Booher S, et al. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002, 87:5104-5112.
90. Stanton RP Surgery for fibrous dysplasia. J Bone Miner Res 2006, 21(Suppl. 2):P105-P109.
91. Enneking WF, Gearen PF Fibrous dysplasia of the femoral neck. Treatment by cortical bone-grafting. J Bone Joint Surg Am 1986, 68:1415-1422.
92. Ippolito E, Bray EW, Corsi A, et al. Natural history and treatment of fibrous dysplasia of bone: a multicenter clinicopathologic study promoted by the European Pediatric Orthopaedic Society. J Pediatr Orthop 2003, 12:155-177.
93. Lee JS, FitzGibbon E, Butman JA, et al. Normal vision despite narrowing of the optic canal in fibrous dysplasia. N Engl J Med 2002, 347:1670-1676.
94. Chapurlat RD Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 2006, 21(Suppl. 2):P114-P119.
95. Kelly MH, Brillante B, Collins MT Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions. Osteoporos Int 2007, 19:57-63.
96. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003, 88:4569-4575.
97. Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007, 92:2100-2106.
98. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003, 143:60-66.
99. Mieszczak J, Eugster EA Treatment of precocious puberty in McCune-Albright syndrome. Pediatr Endocrinol Rev 2007, 4(Suppl. 4):419-422.